Literature DB >> 9207370

Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist.

E Cenci1, A Mencacci, G Del Sero, F Bistoni, L Romani.   

Abstract

Resistance or susceptibility to disseminated and mucosal Candida albicans infections in mice correlates with the development of protective or nonprotective T helper (Th) cell responses. To determine whether immunomodulatory activity on Th cell functions is an effect beyond that provided by antifungal therapy, mice with disseminated or gastrointestinal infection were treated with amphotericin B or fluconazole and assessed for mortality, fungus burden in the organs, and parameters of Th cell-dependent immunity. Both antimycotics produced protective CD4+ Th1 cell responses, as revealed by increased production of interleukin (IL)-12 and interferon-y, decreased production of IL-4, delayed-type hypersensitivity to fungal antigen, and the disappearance of antigen-specific IgE. Concomitant neutralization of endogenous IL-4 greatly increased the antifungal efficacy and the Th1-promoting activity of both agents. These results indicate that successful antifungal therapy alone or in combination with cytokine antagonists may rely on the induction of an appropriate Th antifungal cell response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207370     DOI: 10.1086/514027

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

Authors:  S Mizutani; M Endo; T Ino-Ue; M Kurasawa; Y Uno; H Saito; I Kato; K Takesako
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Measurement of T-cell-derived antigen binding molecules and immunoglobulin G specific to Candida albicans mannan in sera of patients with recurrent vulvovaginal candidiasis.

Authors:  C H Little; G M Georgiou; A Marceglia; H Ogedgebe; R E Cone; D Mazza
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 4.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

5.  Dramatic remission of nephrotic syndrome after unusual complication of mucormycosis in idiopathic membranous nephropathy.

Authors:  Wenling Ye; Yingyi Wang; Yubing Wen; Hang Li; Xuemei Li
Journal:  Int Urol Nephrol       Date:  2014-01-11       Impact factor: 2.370

6.  Evaluation of the Induction of Cell-Mediated Immunity Against Candida albicans in a Model of Cutaneous Infection in Newborn 0-Day-Old Mice.

Authors:  O E Flores-Maldonado; A M Montoya; A Andrade; G M González; S A Aguilar-Fernández; M Elizondo-Zertuche; R Chacón-Salinas; H Rocha-Rodríguez; M A Becerril-García
Journal:  Mycopathologia       Date:  2019-10-21       Impact factor: 2.574

7.  Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avenissian; Yue Fu; Scott G Filler; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

8.  CD86 (B7-2), but not CD80 (B7-1), expression in the epidermis of transgenic mice enhances the immunogenicity of primary cutaneous Candida albicans infections.

Authors:  A A Gaspari; R Burns; A Nasir; D Ramirez; R K Barth; C G Haidaris
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 10.  In search of the holy grail of antifungal therapy.

Authors:  Stanley W Chapman; Donna C Sullivan; John D Cleary
Journal:  Trans Am Clin Climatol Assoc       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.